EU/3/01/034: Orphan designation for the treatment of Wegener's granulomatosis

Gusperimus trihydrochloride

Table of contents

Overview

On, 29 March 2001 orphan designation (EU/3/01/034) was granted by the European Commission to Euro Nippon Kajaku GmbH, Germany, for gusperimus trihydrochloride for the treatment of Wegener's granulomatosis.

The sponsorship was transferred to Nordic Group B.V., The Netherlands, in September 2011.

Key facts

Active substance
Gusperimus trihydrochloride
Intented use
Treatment of Wegener's granulomatosis
Orphan designation status
Positive
EU designation number
EU/3/01/034
Date of designation
29/03/2001
Sponsor
Nordic Group B.V.
Siriusdreef 22
2132WT Hoofddorp
The Netherlands
E-mail: info@nordicpharma.com

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

Related content

How useful was this page?

Add your rating